Results 21 to 30 of about 67,431 (260)

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Hatziieremia, S., Mountford, J.C.   +4 more
core   +1 more source

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib

Gastroenterology Research and Practice, 2014
Purpose. This retrospective, nonrandomized study investigated the effect of imatinib rechallenge plus best supportive care (BSC) on overall survival after imatinib and sunitinib treatment for patients with locally advanced or metastatic gastrointestinal ...
Akira Sawaki, Tatsuo Kanda, Yoshito Komatsu, Toshirou Nishida   +3 more
doaj   +1 more source

Avaliação de parâmetros laboratoriais e clínicos de pacientes portadores de leucemia mielóide crônica submetidos ao tratamento com mesilato de imatinibe e sua relação com alterações observadas no estroma da medula óssea Correlation between laboratory and clinical parameters of chronic myeloid leukemia patients treated with imatinib mesylate and its relationship with stromal changes observed in bone marrow biopsy [PDF]

, 2007
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-graduação em FarmáciaA leucemia mieloide cronica (LMC) e uma doenca mieloproliferativa clonal, responsavel por 14% de todos os casos de ...
Caroline R. de Jesus, Jesus, Caroline Regina de   +1 more
core   +1 more source

Effects of imatinib on vascular insulin sensitivity and free fatty acid transport in early weight gain.

PLoS ONE, 2021
BackgroundVascular endothelial dysfunction is an essential part of the pathophysiology of type 2 diabetes and its complications. In type 2 diabetes, endothelial dysfunction is characterized by reduced insulin signaling and increased transendothelial ...
Camiel V J Box, Amandeep K Sandhu, Alexander H Turaihi, Pan Xiaoké, Geesje Dallinga-Thie, Jurjan Aman, Etto C Eringa   +6 more
doaj   +1 more source

Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background This retrospective series reports outcomes and prognostic factors for advanced chordoma (AC) treatment with molecular targeted therapies (MTTs) in different treatment lines. Methods This is a retrospective series of 57 patients with AC treated between 2004 and 2023 at one of seven participating sarcoma centres.
Lipplaa A, Hindi N, Teterycz P, Young RJ, Boukonavis I, Cruz J, Martinez-Trufero J, Speetjens F, Peul W, van der Wal RJP, Gelderblom H.   +10 more
europepmc   +2 more sources

Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation [PDF]

, 2012
The mitochondrial respiratory chain (MRC) consists of protein complexes I, II, III, IV and V that support oxidative phosphorylation (OXPHOS), which depends on electron transport to generate adenosine triphosphate (ATP).
Flis, Krzysztof, Skorski, Tomasz, Bhatia, Ravi, Irvine, David, Bhatia, R., Copland, Mhairi, Irvine, D., Copland, M., Skorski, T., Flis, K.   +9 more
core   +1 more source

Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy [PDF]

, 2010
Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis.
Jørgensen, Heather G., Jorgensen, Heather G., Tessa L. Holyoake, Heather G. Jørgensen, Scobie, Linda; id_orcid, Elliott, Moira A., Scobie, Linda, Crossan, Claire, Hatziieremia, Sophia, Zhou, Peixun; id_orcid, Elliott, Moira A, Sophia Hatziieremia, Michie, Alison M, Holyoake, Tessa L., Holyoake, Tessa L, Jørgensen, Heather G, Alison M. Michie, Halbert, Gavin W., Linda Scobie, Gavin W. Halbert, Moira A. Elliott, Claire Crossan, Michie, Alison M., Peixun Zhou, Halbert, Gavin W, Zhou, Peixun   +25 more
core   +1 more source

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients

Drug Design, Development and Therapy, 2022
Marwa S Hamza,1 Samia A Shouman,2 Raafat Abdelfattah,3 Heba S Moussa,4 Mervat M Omran2 1Clinical Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt; 2Pharmacology Unit, Cancer Biology ...
Hamza MS, Shouman SA, Abdelfattah R, Moussa HS, Omran MM   +4 more
doaj  

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

Pharmaceutics, 2022
The registered dose for imatinib is 400 mg/d, despite high inter-patient variability in imatinib plasmatic exposure. Therapeutic drug monitoring (TDM) is routinely used to maximize a drug’s efficacy or tolerance.
Hyacinthe Johnson-Ansah, Benjamin Maneglier, Françoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valérie Coiteux, Laurent Sutton, Wajed Abarah, Camille Pouaty, Jean-Michel Pignon, Bachra Choufi, Sorin Visanica, Bénédicte Deau, Laure Morisset, Emilie Cayssials, Mathieu Molimard, Stéphane Bouchet, François-Xavier Mahon, Franck Nicolini, Philippe Aegerter, Jean-Michel Cayuela, Marc Delord, Heriberto Bruzzoni-Giovanelli, Philippe Rousselot   +25 more
doaj   +1 more source

Lack of Association between C1236T, G2677T/A and C3435T Variants of the ABCB1 Gene and Imatinib Response in Iranian Chronic Myeloid Leukemia Patients [PDF]

Journal of Sciences, Islamic Republic of Iran, 2021
Imatinib introduction caused to improve the clinical outcomes of chronic myeloid leukemia (CML) patients. Despite the significant effects of Imatinib, pharmacogenetic variables induced treatment resistant is also observed.
Maedeh Khosravi, Zahra Khalaj, Negar Nouri, Malihe Najaflu, Valiollah Mehrzad, Mohammad Forat-Yazdi, Fariborz Mokarian, Mansour Salehi   +7 more
doaj   +1 more source